CN112805282A - 吲唑-甲酰胺衍生物及其用途 - Google Patents

吲唑-甲酰胺衍生物及其用途 Download PDF

Info

Publication number
CN112805282A
CN112805282A CN201980064129.XA CN201980064129A CN112805282A CN 112805282 A CN112805282 A CN 112805282A CN 201980064129 A CN201980064129 A CN 201980064129A CN 112805282 A CN112805282 A CN 112805282A
Authority
CN
China
Prior art keywords
compound
chf
radical
alkyl
och
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980064129.XA
Other languages
English (en)
Inventor
金传飞
郝格非
许腾飞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Guangdong HEC Pharmaceutical
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of CN112805282A publication Critical patent/CN112805282A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Abstract

本发明公开了吲唑‑甲酰胺衍生物及其用途，为一类吲唑‑甲酰胺衍生物以及包含该类化合物的药物组合物，可作为5‑HT4受体激动剂，制备这类化合物和药物组合物的方法，以及它们在制备治疗与5‑HT4受体活性相关的疾病，如便秘型过敏性肠综合征(IBS‑C)的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201980064129.XA 2019-09-12 2019-09-12 吲唑-甲酰胺衍生物及其用途 Pending CN112805282A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/105538 WO2021046789A1 (zh) 2019-09-12 2019-09-12 吲唑-甲酰胺衍生物及其用途

Publications (1)

Publication Number Publication Date
CN112805282A true CN112805282A (zh) 2021-05-14

Family

ID=74866886

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980064129.XA Pending CN112805282A (zh) 2019-09-12 2019-09-12 吲唑-甲酰胺衍生物及其用途

Country Status (2)

Country Link
CN (1) CN112805282A (zh)
WO (1) WO2021046789A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1922175A (zh) * 2004-02-18 2007-02-28 施万制药 作为5－ht4受体激动剂的吲唑－甲酰胺化合物
CN101080406A (zh) * 2004-12-22 2007-11-28 施万制药 吲唑－甲酰胺化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1922175A (zh) * 2004-02-18 2007-02-28 施万制药 作为5－ht4受体激动剂的吲唑－甲酰胺化合物
CN101080406A (zh) * 2004-12-22 2007-11-28 施万制药 吲唑－甲酰胺化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
陈芬儿 主编: "《基础药物设计学》", 30 November 1995, 华中理工大学出版社 *

Also Published As

Publication number Publication date
WO2021046789A1 (zh) 2021-03-18

Similar Documents

Publication Publication Date Title
CN110437205B (zh) 吡啶烯基哌啶衍生物及其用途
CN111004214B (zh) 吡啶酰基哌啶衍生物及其用途
CN111333648B (zh) 8-取代的芳香环乙烯基黄嘌呤衍生物及其用途
CN110240557B (zh) 吡咯烷酰胺衍生物及其用途
CN110981876B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN111187251A (zh) 吡啶酰基哌啶衍生物及其用途
CN111187252A (zh) 吡啶酰基氮杂螺庚烷衍生物及其用途
CN109988170B (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN112300165B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN111018856B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN107759620B (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其使用方法和用途
CN111072676B (zh) 含氮稠合三环衍生物及其用途
CN110950843B (zh) 取代的苯酰胺衍生物及其用途
CN110963999B (zh) 2,3-二氢苯并呋喃酰胺衍生物及其用途
CN109734712B (zh) 芳基或杂芳基取代的吡咯烷酰胺衍生物及其用途
CN110938064B (zh) N-取代哌啶酰胺衍生物及其用途
CN110938068B (zh) N-(吗啉-2-基甲基)酰胺衍生物及其用途
CN112010818B (zh) 吗啉酰胺衍生物及其用途
CN112805282A (zh) 吲唑-甲酰胺衍生物及其用途
CN108863983B (zh) 亚氨基噻二嗪二氧化物衍生物及其用途
CN108912029B (zh) 含氮杂环酰胺衍生物及其用途
CN108997328B (zh) 亚氨基噻二嗪二氧化物衍生物及其用途
CN110845402A (zh) 吡啶亚甲基哌嗪衍生物及其用途
CN111072604B (zh) α-氨基酰胺衍生物及其用途
CN109796447B (zh) 亚氨基噻二嗪二氧化物衍生物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210514

RJ01 Rejection of invention patent application after publication